Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Net Margin (2016 - 2025)

Historic Net Margin for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to 86.15%.

  • China Pharma Holdings' Net Margin rose 154600.0% to 86.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 78.72%, marking a year-over-year increase of 68500.0%. This contributed to the annual value of 104.58% for FY2024, which is 606700.0% down from last year.
  • China Pharma Holdings' Net Margin amounted to 86.15% in Q3 2025, which was up 154600.0% from 51.51% recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Net Margin peaked at 24.28% during Q1 2023, and registered a low of 155.48% during Q2 2024.
  • Its 5-year average for Net Margin is 61.34%, with a median of 54.02% in 2023.
  • As far as peak fluctuations go, China Pharma Holdings' Net Margin plummeted by -1014700bps in 2024, and later surged by 1039700bps in 2025.
  • China Pharma Holdings' Net Margin (Quarter) stood at 33.94% in 2021, then dropped by -28bps to 43.28% in 2022, then crashed by -32bps to 57.32% in 2023, then plummeted by -88bps to 107.98% in 2024, then grew by 20bps to 86.15% in 2025.
  • Its last three reported values are 86.15% in Q3 2025, 51.51% for Q2 2025, and 69.13% during Q1 2025.